Related references
Note: Only part of the references are listed.Recent updates on drug resistance in Mycobacterium tuberculosis
R. Singh et al.
JOURNAL OF APPLIED MICROBIOLOGY (2020)
The mycobacterial cell envelope - a moving target
Charles L. Dulberger et al.
NATURE REVIEWS MICROBIOLOGY (2020)
Second Line Injectable Drug Resistance and Associated Genetic Mutations in Newly Diagnosed Cases of Multidrug-Resistant Tuberculosis
Vangala Ramakrishna et al.
MICROBIAL DRUG RESISTANCE (2020)
A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB
Markus Beutler et al.
PLOS ONE (2020)
Genetics and roadblocks of drug resistant tuberculosis
Joao Perdigao et al.
INFECTION GENETICS AND EVOLUTION (2019)
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs
Simon Tiberi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure
Yanmin Hu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Whole Genome Sequencing of Mycobacterium tuberculosis Clinical Isolates From India Reveals Genetic Heterogeneity and Region-Specific Variations That Might Affect Drug Susceptibility
Jayshree Advani et al.
FRONTIERS IN MICROBIOLOGY (2019)
Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains
Wenjing Wei et al.
EMERGING MICROBES & INFECTIONS (2019)
Mutational analysis of gyrB at amino acids: G481A & D505A in multidrug resistant (MDR) tuberculosis patients
Nasir Mahmood et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2019)
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH
Angelo Iacobino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance
Nabila Ismail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS
Rui Pi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Heterogeneity of ROS levels in antibiotic-exposed mycobacterial subpopulations confers differential susceptibility
Rashmi Ravindran Nair et al.
MICROBIOLOGY-SGM (2019)
Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis
Nathan D. Hicks et al.
MBIO (2019)
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization
Natasha Strydom et al.
PLOS MEDICINE (2019)
Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues
Conor J. Meehan et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures
Yana R. Batyrshina et al.
TUBERCULOSIS (2019)
Evaluation of Whole-Genome Sequence Method to Diagnose Resistance of 13 Anti-tuberculosis Drugs and Characterize Resistance Genes in Clinical Multi-Drug Resistance Mycobacterium tuberculosis Isolates From China (vol 10, 1741, 2019)
Xinchang Chen et al.
FRONTIERS IN MICROBIOLOGY (2019)
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
Keertan Dheda et al.
LANCET RESPIRATORY MEDICINE (2019)
Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Payam Nahid et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes
Dimitrios Evangelopoulos et al.
NATURE COMMUNICATIONS (2019)
Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis
Bharati Pandey et al.
SCIENTIFIC REPORTS (2019)
Hypoxic Non-replicating Persistent Mycobacterium tuberculosis Develops Thickened Outer Layer That Helps in Restricting Rifampicin Entry
Kishor Jakkala et al.
FRONTIERS IN MICROBIOLOGY (2019)
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis
Sander P. van Rijn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance
Nabila Ismail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria
Yingjun Liu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis
Keertan Dheda et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis
Chao Chen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Identification of Novel Mutations in LprG (rv1411c), rv0521, rv3630, rv0010c, ppsC, and cyp128 Associated with Pyrazinoic Acid/Pyrazinamide Resistance in Mycobacterium tuberculosis
Wanliang Shi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016
Alessandro Mustazzolu et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care
Navisha Dookie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Diagnostic Accuracy and Utility of FluoroType MTBDR, a New Molecular Assay for Multidrug-Resistant Tuberculosis
Margaretha de Vos et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis
Mamoru Fujiwara et al.
TUBERCULOSIS (2018)
Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Vahid Lohrasbi et al.
TUBERCULOSIS (2018)
Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains
H. M. Adnan Hameed et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2018)
Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
Diana Machado et al.
FRONTIERS IN MICROBIOLOGY (2018)
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Nafees Ahmad et al.
LANCET (2018)
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
Caroline Allix-Beguec et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Revising the definition of extensively drug-resistant tuberculosis
Christoph Lange et al.
LANCET RESPIRATORY MEDICINE (2018)
Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum
Jansy P. Sarathy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond
L. D'Ambrosio et al.
PULMONOLOGY (2018)
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Mutations within embCAB Are Associated with Variable Level of Ethambutol Resistance in Mycobacterium tuberculosis Isolates from China
Qing Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis
N. Ismail et al.
DATA IN BRIEF (2018)
Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH
Angelo Iacobino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro
Jees Sebastian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
Paolo Miotto et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Drug resistance mechanisms and novel drug targets for tuberculosis therapy
Md Mahmudul Islam et al.
JOURNAL OF GENETICS AND GENOMICS (2017)
Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era
Ameeruddin Nusrath Unissa et al.
TUBERCULOSIS (2017)
New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria
Mohammad J. Nasiri et al.
FRONTIERS IN MICROBIOLOGY (2017)
Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis
Shuo Zhang et al.
EMERGING MICROBES & INFECTIONS (2017)
Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies
Kelemu Tilahun Kibret et al.
INFECTIOUS DISEASES OF POVERTY (2017)
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Jansy P. Sarathy et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2017)
Evaluation of a new automated Abbott RealTime MTB RIF/INH assay for qualitative detection of rifampicin/isoniazid resistance in pulmonary and extra-pulmonary clinical samples of Mycobacterium tuberculosis
Pilar Ruiz et al.
INFECTION AND DRUG RESISTANCE (2017)
Fighting Tuberculosis by Drugs Targeting Nonreplicating Mycobacterium tuberculosis Bacilli
Angelo Iacobino et al.
INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY (2017)
In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China
Yu Pang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Treatment of Latent Tuberculosis Infection An Updated Network Meta-analysis
Dominik Zenner et al.
ANNALS OF INTERNAL MEDICINE (2017)
Formation, physiology, ecology, evolution and clinical importance of bacterial persisters
Bram Van den Bergh et al.
FEMS MICROBIOLOGY REVIEWS (2017)
Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives
Sebastian M. Gygli et al.
FEMS MICROBIOLOGY REVIEWS (2017)
Antituberculosis drugs: reducing efflux = increasing activity
Liliana Rodrigues et al.
DRUG DISCOVERY TODAY (2017)
Targeting Phenotypically Tolerant Mycobacterium tuberculosis
Ben Gold et al.
MICROBIOLOGY SPECTRUM (2017)
Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy
Caroline M. Pule et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Geographic Differences in the Contribution of ubiA Mutations to High-Level Ethambutol Resistance in Mycobacterium tuberculosis
Subramanya Lingaraju et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
Deepak Almeida et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Antibiotic resistance mechanisms in M-tuberculosis: an update
Liem Nguyen
ARCHIVES OF TOXICOLOGY (2016)
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC
Laura Iannazzo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Modeling the permeability of drug-like molecules through the cell wall of Mycobacterium tuberculosis: an analogue based approach
Sridhara Janardhan et al.
MOLECULAR BIOSYSTEMS (2016)
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Asher Brauner et al.
NATURE REVIEWS MICROBIOLOGY (2016)
Prediction of Drug Penetration in Tuberculosis Lesions
Jansy P. Sarathy et al.
ACS INFECTIOUS DISEASES (2016)
Paradoxical Hypersusceptibility of Drug-resistant Mycobacterium tuberculosis to β-lactam Antibiotics
Keira A. Cohen et al.
EBIOMEDICINE (2016)
Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors
Sarah Schmidt Grant et al.
CELL CHEMICAL BIOLOGY (2016)
Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates
Johana Rueda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis
Jean-Philippe Lanoix et al.
DISEASE MODELS & MECHANISMS (2015)
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Anne Lenaerts et al.
IMMUNOLOGICAL REVIEWS (2015)
Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis
Shuo Zhang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
The association between sterilizing activity and drug distribution into tuberculosis lesions
Brendan Prideaux et al.
NATURE MEDICINE (2015)
ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis
Lei He et al.
TUBERCULOSIS (2015)
The Mycobacterial Cell Wall-Peptidoglycan and Arabinogalactan
Luke J. Alderwick et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)
Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis
Ruben C. Hartkoorn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Rifampin Induces Hydroxyl Radical Formation in Mycobacterium tuberculosis
Giovanni Piccaro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Evaluation of gidB alterations responsible for streptomycin resistance in Mycobacterium tuberculosis
Jitender S. Verma et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Veronique Dartois
NATURE REVIEWS MICROBIOLOGY (2014)
Synthetic Lethality Reveals Mechanisms of Mycobacterium tuberculosis Resistance to β-Lactams
Shichun Lun et al.
MBIO (2014)
Common errors in multidrug-resistant tuberculosis management
Ignacio Monedero et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2014)
Role of the Mmr Efflux Pump in Drug Resistance in Mycobacterium tuberculosis
Liliana Rodrigues et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Dormancy Is Not Necessary or Sufficient for Bacterial Persistence
Mehmet A. Orman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Activities of Drug Combinations against Mycobacterium tuberculosis Grown in Aerobic and Hypoxic Acidic Conditions
Giovanni Piccaro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Microbial Persistence and the Road to Drug Resistance
Nadia R Cohen et al.
CELL HOST & MICROBE (2013)
A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union
C. Bernard et al.
EUROSURVEILLANCE (2013)
Additional Drug Resistance in Mycobacterium tuberculosis Isolates From Resected Cavities Among Patients With Multidrug-Resistant or Extensively Drug-Resistant Pulmonary Tuberculosis
Russell R. Kempker et al.
CLINICAL INFECTIOUS DISEASES (2012)
Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine
Eduardo Abbate et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review
Sophia B. Georghiou et al.
PLoS One (2012)
Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis
Diana Machado et al.
PLOS ONE (2012)
The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance
Jansy Passiflora Sarathy et al.
PHARMACEUTICALS (2012)
Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis
Sharon Y. Wong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Stability, denaturation and refolding of Mycobacterium tuberculosis MfpA, a DNA mimicking protein that confers antibiotic resistance
Sergei Khrapunov et al.
BIOPHYSICAL CHEMISTRY (2011)
Characterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters
Iris Keren et al.
MBIO (2011)
Activity of Drug Combinations against Dormant Mycobacterium tuberculosis
Perla Filippini et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis
Claudia Sala et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Efflux-Pump-Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of Ethambutol
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae
Kevin A. Nash et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance
Luiz Pedro S. de Carvalho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Clifton E. Barry et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Rv1698 of Mycobacterium tuberculosis represents a new class of channel-forming outer membrane proteins
Axel Siroy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910
Anne J. Lenaerts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis
CT Madsen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis
MR Pasca et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
FbpA-dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of Mycobacterium smegmatis
L Nguyen et al.
JOURNAL OF BACTERIOLOGY (2005)
Requirement of the mymA operon for appropriate cell wall ultrastructure and persistence of Mycobacterium tuberculosis in the spleens of guinea pigs
A Singh et al.
JOURNAL OF BACTERIOLOGY (2005)
Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex
K Buriankova et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Mycobacterium tuberculosis growth at the cavity surface:: a microenvironment with failed immunity
G Kaplan et al.
INFECTION AND IMMUNITY (2003)
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program
MI Voskuil et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling
JC Betts et al.
MOLECULAR MICROBIOLOGY (2002)
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide
YM Hu et al.
JOURNAL OF BACTERIOLOGY (2000)
Share Paper
